While olfactory assessment has been proposed as a biomarker for preclinical AD diagnosis23–26 and its dysfunction has been repeatedly correlated with cognitive decline in healthy aging27 and grey matter volume loss28,29, its association with cortical tau spreading is still unknown. This evidence concerns the gene MAPT and Alzheimer disease.